Brief Title
Chidamide Combined With Cisplatin in Head and Neck Adenoid Cystic Carcinoma (HNACC)
Official Title
Chidamide Combined With Cisplatin in Recurrent or Metastatic Head and Neck Adenoid Cystic Carcinoma: A Prospective, Open-label, Phase II Study of a Single Center
Brief Summary
The investigators conducted this study to evaluate the efficacy of Chidamide combined with cisplatin in recurrent or metastatic head and neck adenoid cystic carcinoma.
Detailed Description
Adenoid cystic carcinomas (ACCs) constitute of 1% of head and neck cancers. This type of tumor grows slowly with a high potential of local recurrence. Approximately 50% of patients develop distant metastases, and 33% patients die within 2 years. The initial therapy of these malignancies consists of surgical resection followed by radiotherapy. Systemic therapy is crucial in the management of recurrent and metastatic disease. However, nowadays, there were no standard chemoimmunotherapy regimes. Previous report showed that overall response rate was only less than 10% using single-agent chemotherapies, and the best results were achieved by cisplatin. Chidamide is a new benzamide class of histone deacetylase inhibitor with marked antitumor activity. And a phase I study has showed that one of three patients with submandibular adenoid cystic carcinoma achieved a partial response treated with Chidamide. The investigators conducted this study to evaluate the efficacy of Chidamide combined with cisplatin in recurrent or metastatic head and neck adenoid cystic carcinoma, in order to find a potential promising way to treat this kind of disease.
Study Phase
Phase 2
Study Type
Interventional
Primary Outcome
Overall response rate (ORR)
Secondary Outcome
Disease control rate (DCR)
Condition
Adenoid Cystic Carcinomas
Intervention
Chidamide combined with cisplatin
Study Arms / Comparison Groups
Chidamide combined with Cisplatin
Description: Chidamide: 30mg,PO,biw one week before cycle 1 treatment Cisplatin 25mg/m2 ivgtt D1-3 Chidamide :20mg PO Biw, 2 week on , 1 week off
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Drug
Estimated Enrollment
22
Start Date
June 6, 2018
Completion Date
June 1, 2020
Primary Completion Date
March 1, 2020
Eligibility Criteria
Inclusion Criteria: 1. Age range 18-75 years old 2. Histological confirmed recurrent or metastatic head and neck adenoid cystic carcinoma 3. Unable to treat with surgery/radiotherapy, or previously failure to non-cisplatin systematic treatment; 4. Eastern Cooperative Oncology Group performance status 0 to 2; 5. Patients have written informed consent to participate in the study; 6. anticipated to live ≧3 months; 7. Absolute neutrophil count ≥ 1.5×109/L,platelet ≥ 100×109/L,hemoglobin ≥ 90 g/L 8. total bilirubin < 1.5×upper limit of normal(ULN), ALT and AST < 3× ULN 9. serum creatine <1.5×ULN, and creatinine clearance rate (CCR) ≥ 50 ml/min 10. Ultrasonic cardiogram showed left ventricle ejection fraction ≥ 50%, EKG showed no signs of myocardial ischemia, with no previous arrhythmia which need pharmacological intervention. 11. Measurable disease was defined as at least one lesion ≥1.5 cm in length-diameter and ≥0.5 cm in short-diameter by CT. Exclusion Criteria: 1. Previously treated with HDACi; 2. Treated with cisplatin-contained regimes in the past half of the year, and not achieving PR/CR; 3. History of other malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix; 4. HIV, HCV, or syphilis infection; 5. Pregnant or lactating women; 6. Serious uncontrolled infection; 7. Severe neurol of mental illness, including dementia and epilepsy; 8. Having contraindications to the use of oral medication, such as unable to swallow, nausea and vomiting, chronic diarrhea or suffering from a bowel obstruction; 9. Participated in other clinical trials in 4 weeks; 10. Other coexisting diseases or situations that may cause patients to fail to complete clinical trials; 11. History of QTc interval prolongation (Male >450ms,Female >470ms), ventricular tachycardia, auricular fibrillation, heart block of more than II degrees, myocardial infarction in 1 year, congenital heart disease, with symptomatic coronary heart disease requiring medication.
Gender
All
Ages
18 Years - 75 Years
Accepts Healthy Volunteers
No
Contacts
Kai Xue, MD, 021-64175590, [email protected]
Location Countries
China
Location Countries
China
Administrative Informations
NCT ID
NCT03639168
Organization ID
CC-HN-1
Responsible Party
Principal Investigator
Study Sponsor
Fudan University
Study Sponsor
Kai Xue, MD, Principal Investigator, Department of medical oncology,Fudan University, Shanghai Cancer Center
Verification Date
February 2020